or Try an Advanced Search...

    Stocks in the Drug Manufacturers - General Industry

    Sector: Healthcare

    Drug Manufacturers - General is an industry that produces pharmaceuticals, biologics, and medical devices. This industry includes companies that manufacture, market, and distribute prescription and over-the-counter drugs, as well as those that produce and market medical devices. Companies in this industry may also conduct research and development activities related to drug and device development.

    Symbol Grade Name % Change
    MIRA B MIRA Pharmaceuticals, Inc. -13.24
    OGN D Organon & Co. -3.78
    SCLX D Scilex Holding Company 1.16

    Related ETFs - ETFs which own at least one of the above listed Drug Manufacturers - General stocks.

    Symbol Grade Name Weight
    CSD A Guggenheim Spin-Off ETF 3.67
    PSCH C PowerShares S&P SmallCap Health Care Portfolio 3.01
    XPH B SPDR S&P Pharmaceuticals ETF 2.93
    FTXH C First Trust Nasdaq Pharmaceuticals ETF 2.72
    PILL B Direxion Daily Pharmaceutical & Medical Bull 3X Shares ETF 2.09
    IHE D iShares U.S. Pharmaceutical ETF 1.75
    OUSM C O'Shares FTSE Russell Small Cap Quality Dividend ETF 1.7
    COWS C Amplify Cash Flow Dividend Leaders ETF 1.56
    FXH C First Trust Health Care AlphaDEX 1.55
    DES C SmallCap Dividend Fund 1.26
    BSMC C Brandes U.S. Small-Mid Cap Value ETF 1.24
    CAFG A Pacer US Small Cap Cash Cows Growth Leaders ETF 1.18
    EQUL C IQ Engender Equality ETF 1.13
    IBHH A iShares iBonds 2028 Term High Yield and Income ETF 1.0
    SIXS C 6 Meridian Small Cap Equity ETF 0.9
    VMAX B Hartford US Value ETF 0.84
    HIDV B AB US High Dividend ETF 0.73
    VIOV B Vanguard S&P Small-Cap 600 Value ETF 0.71
    NDOW F Anydrus Advantage ETF 0.69
    SLYV B SPDR S&P 600 Small Cap Value ETF (based on S&P SmallCap Value Index 0.67
    Compare ETFs
    Compare CSD to FTXH Compare CSD to PILL Compare PSCH to XPH

        Recent Signals

        Date Stock Signal Type
        2024-11-01 MIRA Wide Range Bar Range Expansion
        2024-11-01 MIRA Upper Bollinger Band Walk Strength
        2024-11-01 OGN Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
        2024-11-01 SCLX Crossed Above 50 DMA Bullish
        2024-11-01 SCLX NR7 Range Contraction

        Recent News for Drug Manufacturers - General Stocks

        Date Stock Title
        Nov 1 OGN Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)
        Oct 31 OGN Organon & Co. 2024 Q3 - Results - Earnings Call Presentation
        Oct 31 OGN Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
        Oct 31 OGN Organon in charts: Revenue from Europe and Canada rises most among geographies in Q3
        Oct 31 OGN Organon Non-GAAP EPS of $0.87 misses by $0.03, revenue of $1.58B beats by $20M
        Oct 31 OGN Organon Reports Results for the Third Quarter Ended September 30, 2024
        Oct 30 OGN Organon Q3 2024 Earnings Preview: Dermavant purchase in focus
        Oct 30 OGN FDA accepts Organon BLA for Prolia/Xgeva biosimilar
        Oct 30 OGN US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
        Oct 29 MIRA MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
        Oct 28 MIRA MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
        Oct 28 OGN Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
        Oct 28 MIRA MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain
        Oct 27 MIRA Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024